Endocrine Abstracts

Introduction: The metabolic syndrome (MS) is a real public health problem on a global scale. People with MS are at increased risk not only for cardiovascular diseases but also for neoplasia. The aim of our study is to determine the prevalence of MS in patients with digestive neoplasia and to study the impact of MS on the epidemiological, clinical profile and prognosis of digestive neoplasms.

Material and methods: This is a retrospective study including patients with digestive neoplasia who were hospitalized in our department between January 2015 and June 2016. For all patients, BMI, waistline, systolic and diastolic blood pressure, HDL cholesterol, triglycerides, and blood glucose levels were determined. A MS was defined according to the criteria of the International Diabetes Federation IDF 2005.

Results: 78 patients were included (40 men and 38 women), with an average age of 61.7 years (between 28 and 89 years). The digestive neoplasias found were: colorectal cancer (CRC) (n=21.27%), hepatocellular carcinoma (CHC) on cirrhosis liver (n=18.23%), gastric cancer (n=13.16.7%), Cholangiocarcinoma (n=10.12.7%), pancreatic cancer (n=9.11.5%), oesophageal cancer (n=3.8%), small bowel lymphoma and a Cancer of the gall bladder in two cases each (n=2.6%). The mean tumor size at diagnosis was 6.2 cm (1.5–18 cm). The tumor was metastatic in 26 cases (33.3%). MS was present in 29 cases (37.2%). The analytical study found that MS was more frequently found in female patients (50% versus 25%, P=0.022), older patients (68.2 years versus 58 years, P=0.001) and having a CRC (57% versus 29%, P=0.027). However, the presence of a MS did not influence the average survival of patients (10.3 months versus 8 months, P=0.138).

Conclusion: In our study, more than one-third of patients had MS. It was associated with an older age, the female sex and the CRC. However, diagnosis and management of MS remains difficult in these patients because of the malnutrition and weight loss caused by the disease.